Drug potency -- what happens in space?

Some of the Pharmaceuticals intended for the treatment of minor illnesses of astronauts in space may require special packaging and reformulation to remain stable for long periods in the space environment. That's according to Dr. Putcha and her colleagues from NASA, Johnson Space Centre. Their findings, published online in The AAPS Journal suggest that some of the pharmaceuticals stored on space flights may have shorter shelf-life than they do on Earth.

Pharmaceuticals used on space flights are packed and dispensed in special flight-certified containers and stored in compact flight kits. They may be exposed to the unique environ-mental factors of such as radiation and excessive vibration in addition to variations in temperature and humidity.

Scientists at the Johnson Space Centre investigated whether pharmaceuticals undergo degradation in space and, if so, which environmental variables in space may affect the stability of the medications in space. They compared physical and chemical changes in 35 formulations contained in identical pharmaceutical kits stowed on the (ISS) and on Earth.

After stowage for 28 months in space, they found that a higher percentage of the medica-tions from each flight kit had a lower active content than the controls on the ground. They also saw no variation in the temperature or humidity levels between Earth and in space.

Putcha and her colleagues suggest that exposure to the chronic low dose of ionizing radi-ation as well as repackaging of solid medications may be contributing factors for phar-maceutical stability in space.

The authors conclude: "It is important to characterize space-specific degradation products and toxicity limits using ground-based analogue environments of space that include proton and heavy ion radiation, vibration and multiple gravity conditions. This information can facilitate research for the development of space-hardy pharmaceuticals and packaging technologies."

More information: Du B, Putcha L et al (2011). Evaluation of physical and chemical changes in pharmaceuticals flown on space missions. The AAPS Journal. DOI 10.1208/s12248-011-9270-0

add to favorites email to friend print save as pdf

Related Stories

NASA celebrates five years on the ISS

Oct 25, 2005

The National Aeronautics and Space Administration is celebrating five years of space flight on the international space station with two weeks of events

NASA gets ready for another space mission

Mar 31, 2008

Now that the latest space shuttle Endeavour mission is completed, the U.S. space agency said it's preparing for the May launch of space shuttle Discovery.

Space Station Astronaut Records Muscle Activity for Study

Aug 03, 2005

Expedition 11 NASA ISS Science Officer John Phillips conducted his fourth session of the Foot/Ground Reaction Forces during Spaceflight, or FOOT experiment. Phillips wore the instrumented Lower Extremity Monitoring Suit, ...

Space officials talk about the ISS

Jan 23, 2007

The heads of the International Space Station partners met at the European Space Agency headquarters in Paris Tuesday to review ISS cooperation.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

User comments